JP Morgan Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and raises the price target from $31 to $39.
June 18, 2024 | 2:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Jessica Fye maintains an Overweight rating on Mirum Pharmaceuticals and raises the price target from $31 to $39.
The increase in the price target from $31 to $39 by a reputable analyst at JP Morgan is a positive signal for investors, indicating confidence in the company's future performance. This is likely to result in a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100